Advaxis, Inc. #ADXS announced that it intends to withdraw its Marketing Authorization Application, MAA, in the European Union for axalimogene filolisbac to treat metastatic cervical cancer in patients who progress beyond first-line therapy. The action follows feedback from the European Medicines Agency, EMA, that additional data to support a conditional approval are required.